The Therapeutic Goods Administration (TGA) is advancing its implementation of the ICH eCTD (Electronic Common Technical Document) version 4.0, aiming to enhance global harmonization and streamline regulatory submissions.
The FDA's accelerated approval pathway has always balanced speed with rigorous evaluation.
The year 2024 brought significant strides in regulatory submissions, but 2025 is set to revolutionize the field even further. For regulatory professionals, publishers, and life sciences companies, the upcoming year promises to bring unprecedented changes. With the integration of advanced technologies and a focus on global standards, the regulatory submission process is becoming more efficient and transparent.
Implementing an eCTD (electronic Common Technical Document) submission software is a significant step for any organization involved in regulatory affairs. The right software can streamline the submission process, ensure compliance with regulatory requirements, and improve overall efficiency. However, successful implementation requires careful planning and execution. Here are some best practices to guide companies and regulatory professionals through this process.
The regulatory landscape has been abuzz with anticipation for the USFDA's update on eCTD v4.0. Regulatory professionals and life sciences companies have been eagerly awaiting news on the next steps for this critical submission format. Finally, a few months ago, the USFDA announced that, starting from September 16, 2024, they would support the electronic submission of eCTD v4.0 for new applications.
Regulatory audits are an unavoidable reality in the pharmaceutical and life sciences industries. Agencies like the FDA, EMA, and other local regulatory bodies meticulously review documentation, processes, and data integrity. A single overlooked document, inconsistency, or human error can lead to severe consequences such as delays, financial penalties, and product recalls. The critical question is: Are you truly prepared for your next regulatory audit?
The pharmaceutical industry operates in a complex Regulatory environment where precision, speed, and compliance are non-negotiable. From managing multi-regional submissions to ensuring data accuracy under tight deadlines, pharmaceutical companies face immense pressure to stay compliant while bringing their products to market swiftly.
In today’s heavily regulated life sciences landscape, the role of regulatory submission software has become pivotal for companies seeking to bring products to market efficiently and maintain global compliance. Regulatory submission software is a digital solution streamlining the submission process, from document preparation to final submission tracking. These systems automate essential tasks, ensuring that life sciences companies remain compliant, avoid costly delays, and maintain accurate records based on various HA guidelines.
Over the years, international organizations and the pharmaceutical industry have observed the detrimental effects it has on the environment. During all stages of their life cycle, medical products interact with the environment, but the production stage is where most effects take place.
Pharmaceutical products are released in the environment through intricate web of pathways which makes this issue multifaceted; pinpointing one direct or singular source is not possible. There three ways in which products are released into the environment
Ever wondered about the drug labels and what goes into creating the content for it? Of course it serves the purpose of providing information about the ingredients, usage and what the medication is used for but how do health authorities standardize the content structure for it? The answer is SPL (Structured Product Labelling) and SPM (Structured Product Monograph). While the two names might sound similar, they serve different purposes in the world of medicine.